Figures & data
Table 1. COPD treatment algorithm employed by NHS Tayside. The algorithm recommends that a combined inhaled steroid and long-acting bronchodilator should be prescribed only if the patient has persistent breathlessness or repeated exacerbations despite optimal bronchodilator therapy (defined in step 3 as LABA and LAMA co-prescribing, coloured blue) and should be discontinued if no benefit after 4 weeks
Table 2. LABA/LAMA fixed-dose combinations in late-stage clinical development
Figure 1. Comparison of FEV1 for QVA149 versus fluticasone/salmeterol. The ILLUMINATE double-blind, randomised trial of 523 patients. The primary study endpoint was FEV1 AUC0–12 h at 26 weeks for QVA149 vs. salmeterol/fluticasone (Citation40). At Week 26, FEV1 AUC0–12 h was significantly higher with QVA149 compared with fluticasone/salmeterol combination, with a significant and clinically meaningful treatment difference of 138 mL (95% CI 100–176; p < 0.0001).
![Figure 1. Comparison of FEV1 for QVA149 versus fluticasone/salmeterol. The ILLUMINATE double-blind, randomised trial of 523 patients. The primary study endpoint was FEV1 AUC0–12 h at 26 weeks for QVA149 vs. salmeterol/fluticasone (Citation40). At Week 26, FEV1 AUC0–12 h was significantly higher with QVA149 compared with fluticasone/salmeterol combination, with a significant and clinically meaningful treatment difference of 138 mL (95% CI 100–176; p < 0.0001).](/cms/asset/b7a7e093-8f12-4c10-93bf-59fbe572158e/icop_a_995288_f0001_b.gif)